SCHEMBL3620228

SCHEMBL3620228

Ic1ccn2c(-c3ccccc3)nnc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.51
PDGFRA P16234 1/20 0.51
CSNK1A1 P48729 1/20 0.51
CDK7 P50613 1/20 0.51
BTK Q06187 1/20 0.51
MAP4K2 Q12851 1/20 0.51
AURKB Q96GD4 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
KDM4E B2RXH2 6/20 0.46
HSD17B10 Q99714 3/20 0.46
KMT2A Q03164 2/20 0.46
BRD4 O60885 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
CREBBP Q92793 1/20 0.39
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498954 0.81 DNMT1 (0.54) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL3619423 0.80 TNKS (0.38) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL3623290 0.78 HSD11B1 (0.47) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL3621998 0.78 HSD11B1 (0.40) KDM4EHSD11B1MAPK14
SCHEMBL6219388 0.76 KDM4E (0.73) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL3622123 0.76 MAPK14 (0.43) KDM4EHSD17B10KMT2AALDH1A1MAPK14
SCHEMBL3620581 0.76 LMNA (0.47) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL3622223 0.75 DNMT1 (0.33) DNMT1
SCHEMBL16332036 0.74 MAPK14 (0.47) ABL1PDGFRACSNK1A1CDK7BTK
SCHEMBL23733338 0.71 ABL1 (0.54) ABL1PDGFRACSNK1A1CDK7BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258122-B2 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL, S.A. (ES) 2012-09-04 US disclosed
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-13 US disclosed
EP-2118100-A1 NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES Almirall, S.A. (ES) 2009-11-18 EP disclosed
WO-2008107125-A1 NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES MAP4K2, MAP3K7, MAPK7 ABL1 114/4885PDGFRA 180/4885CSNK1A1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.